OHSU

IRB #

IRB00009549

Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of REGN668 Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis

Principal Investigator

Eric Simpson

Study Purpose

The purpose of this study is to learn more about a new study drug, REGN668. It is being used for the treatment of atopic dermatitis. The main purposes of this study are to help determine how well different doses (amounts) of the study drug work to treat eczema, and how the body reacts to the study drug.

Medical Condition(s)

Atopic Dermatitis

Eligibility Criteria

1. Male or female, 18 years or older
2. Chronic Atopic dermatitis present for at least 3 years
3. Willing and able to comply with all clinic visits and study-related procedures
4. Able to understand and complete study-related questionnaires

Age Range

18 - No limit

Healthy Volunteers Needed

No

Duration of Participation

34 weeks

Minors Included

No

Contact

Maureen Keene
503-228-7350
keenem@ohsu.edu

Sponsor

Regeneron Pharmaceuticals, Inc.

Recruitment End

12/31/2014

Compensation Provided

Yes

Compensation

50 dollars for each visit


Go Back